- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05473689
Outcomes Post Treatment: Impact on Motor Impairment of Sleep Efficiency in SCI (OPTIMISE SCI Trial)
January 10, 2024 updated by: University Health Network, Toronto
This randomized clinical trial will compare three groups of individuals with cervical/thoracic, complete or incomplete spinal cord injury (SCI) that will undergo: (i) early CPAP therapy in the management of moderate-to-severe sleep-related breathing disorders (SRBDs) among adults at 6 weeks after SCI; (ii) delayed CPAP therapy in the management of moderate-to-severe SRBDs among adults at 22 weeks after SCI; and (iii) no treatment as they either have mild or no SRBD.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
66
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Mitsue Aibe, MD
- Phone Number: 6285 4165973422
- Email: Mitsue.Aibe@uhn.ca
Study Contact Backup
- Name: Abrity Gomes
- Phone Number: 6285 4165973422
- Email: abrity.gomes@uhn.ca
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M4G 3V9
- Recruiting
- KITE Toronto Research Institute
-
Contact:
- Mitsue Aibe
- Phone Number: 6285 4165973422
- Email: Mitsue.Aibe@uhn.ca
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- English-speaking adults (18 years of age or older)
- Acute (≤ 30 days after injury), cervical/thoracic (injury level at C2 to T12), complete or incomplete (AIS A to D) SCI
- Not being treated for sleep apnea prior to the spinal cord impairment onset.
Exclusion Criteria:
- Non-traumatic spinal cord disease at risk for neurologic progression (e.g., demyelinating spine diseases such as neuromyelitis optica and multiple sclerosis, spinal cord malignancy)
- Concomitant diseases of the central nervous system
- Preinjury chronic pain
- Other pre-existing diseases of the central nervous system
- Significant psychiatric disorders with recent episode of exacerbation
- Neuromuscular diseases
- Current substance misuse
- Known history of primary hypersomnia or secondary hypersomnia of any cause except for SRBDs (e.g., hypothyroidism, moderate or severe iron deficiency anemia, infections, depression, kidney failure, chronic fatigue syndrome, neurodegenerative diseases, and myotonic dystrophy)
- Epilepsy
- Vitamin B12 deficiency
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Early-CPAP therapy group
Individuals diagnosed with moderate-to-severe sleep-related breathing disorders (SRBDs) who will start CPAP therapy within the first 6 weeks after SCI.
|
Continuous positive airway pressure (CPAP) therapy for moderate-to-severe sleep-related breathing disorders.
|
Active Comparator: Delayed-CPAP therapy group
Individuals diagnosed with moderate-to-severe SRBDs who will start on CPAP therapy at the 5th month after SCI.
|
Continuous positive airway pressure (CPAP) therapy for moderate-to-severe sleep-related breathing disorders.
|
No Intervention: Non-CPAP therapy group
Individuals who are diagnosed with no or mild SRBD.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in International Standards for Neurological Classification of SCI (ISNCSCI) motor subscore from baseline to 6 months after recruitment
Time Frame: From baseline to 6 months after recruitment
|
Motor assessment of muscles in the upper and lower extremities (100: normal; 0: complete paresis)
|
From baseline to 6 months after recruitment
|
Change in International from baseline to 6 months after recruitment Standards for Neurological Classification of SCI (ISNCSCI) sensory subscore
Time Frame: From baseline to 6 months after recruitment
|
Sensory assessment of dermatomes in the upper and lower extremities (224: normal; 0: no sensory function)
|
From baseline to 6 months after recruitment
|
Change in Spinal Cord Independence Measure (SCIM) - version III - score from baseline to 6 months after recruitment
Time Frame: From baseline to 6 months after recruitment
|
The SCIM scores varies from 0 to 100 and includes the following subscores: self-care (0-20); respiration and sphincter management (0-40); mobility (0-40).
|
From baseline to 6 months after recruitment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Fatigue Severity Scale (FSS) from baseline to 6 months after recruitment
Time Frame: From baseline to 6 months after recruitment
|
The FSS scores vary from 9 (normal) to 56 (the most severe degree of fatigue)
|
From baseline to 6 months after recruitment
|
Change in Depression, Anxiety & Stress Scales- 21 (DASS-21) score from baseline to 6 months after recruitment
Time Frame: From baseline to 6 months after recruitment
|
The DASS-21 scores vary from 0 (normal) to 42 (most severe symptoms of depression, anxiety and stress).
|
From baseline to 6 months after recruitment
|
Change in Patient Health Questionnaire (PHQ-9) score from baseline to 6 months after recruitment
Time Frame: From baseline to 6 months after recruitment
|
The PHQ-9 scores vary from 0 to 27, which means: 0-4 is the normal or minimal; 5-9 if the person is mildly depressed; 10-14 if the person is moderately depressed; 15-19 if the person has moderately severe depression; and 20-27 if the person is severely depressed.
|
From baseline to 6 months after recruitment
|
Change in Medical Outcomes Study Sleep Scale (MOS-SS) from baseline to 6 months after recruitment
Time Frame: From baseline to 6 months after recruitment
|
Scores for the sleep disturbance, snoring, respiratory problems, sleep adequacy, and daytime somnolence dimensions range from 0 (normal) to 100.
|
From baseline to 6 months after recruitment
|
Change in Montreal Cognitive Assessment (MoCA test) score from baseline to 6 months after recruitment
Time Frame: From baseline to 6 months after recruitment
|
The MoCA test scores vary from 0 to 30 (normal).
|
From baseline to 6 months after recruitment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Julio C Furlan, MD, FRCPC, KITE Research Institute, University Health Network
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 15, 2022
Primary Completion (Estimated)
July 31, 2024
Study Completion (Estimated)
July 31, 2025
Study Registration Dates
First Submitted
July 19, 2022
First Submitted That Met QC Criteria
July 21, 2022
First Posted (Actual)
July 26, 2022
Study Record Updates
Last Update Posted (Actual)
January 11, 2024
Last Update Submitted That Met QC Criteria
January 10, 2024
Last Verified
October 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 21-6214
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
The UHN REB needs to approve any plan to share data from this RCT.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Spinal Cord Injuries
-
Khon Kaen UniversityUnknownInjuries, Spinal Cord
-
Universidade do Vale do ParaíbaCompletedInjuries, Spinal Cord
-
InVivo TherapeuticsTerminated
-
Ekso BionicsBurke Medical Research InstituteCompletedInjuries, Spinal CordUnited States
-
ReWalk Robotics, Inc.Unknown
-
Shepherd Center, Atlanta GACompletedInjuries, Spinal Cord
-
Wroclaw Medical UniversityInstitute of Immunology and Experimental Therapy of the Polish Academy of... and other collaboratorsUnknownComplete Spinal Cord InjuriesPoland
-
M.D. Anderson Cancer CenterActive, not recruitingMetastatic Epidural Spinal Cord CompressionUnited States
Clinical Trials on Continuous positive airway pressure (CPAP) therapy
-
Indiana UniversityNational Heart, Lung, and Blood Institute (NHLBI)Completed
-
University Health Network, TorontoThe Craig H. Neilsen FoundationRecruitingSleep Apnea | Spinal Cord InjuriesCanada
-
University of PennsylvaniaNational Institute on Aging (NIA)Active, not recruitingSleep Apnea, Obstructive | Mild Cognitive ImpairmentUnited States
-
Eileen R. ChasensCompletedSleep Apnea, Obstructive | Diabetes Mellitus, Type 2United States
-
Women's College HospitalUniversity Health Network, TorontoWithdrawnObstructive Sleep Apnea | FibromyalgiaCanada
-
Angeles Sanchez ArmengolBeca de Excelencia de la CICE de la Junta de Andalucia y programa Operativo...Completed
-
Sociedad Española de Neumología y Cirugía TorácicaCompletedObstructive Sleep ApneaSpain
-
St. Olavs HospitalNorwegian University of Science and TechnologyCompletedChronic Disease | Cluster HeadacheNorway
-
McGill UniversityCentre hospitalier de l'Université de Montréal (CHUM); Philips Respironics; Multiple... and other collaboratorsCompletedObstructive Sleep Apnea-hypopnea in Multiple Sclerosis PatientsCanada
-
Chinese Pulmonary Vascular Disease Research GroupCompletedObstructive Sleep Apnea | Coronary Heart DiseaseChina